Home / Health / New Pill Offers Hope for Advanced Breast Cancer
New Pill Offers Hope for Advanced Breast Cancer
17 Nov
Summary
- FDA approved giredestrant (Wilserdly) on Monday for specific breast cancer types.
- The drug is for ER-positive, HER2-negative advanced breast cancer with ESR1 mutations.
- Giredestrant with everolimus showed longer progression-free survival in trials.
The U.S. Food and Drug Administration (FDA) announced the approval of giredestrant (Wilserdly) on Monday, November 16, 2026. This new daily pill offers a treatment option for adults diagnosed with advanced breast cancer.
Specifically, the drug is intended for patients with estrogen receptor (ER)-positive, HER2-negative breast cancer that has spread or advanced into nearby tissue. This approval targets individuals whose tumors possess an ESR1 gene mutation, a common cause for resistance to earlier hormone therapies.
The effectiveness of giredestrant was evaluated in combination with the cancer drug everolimus. In a trial, patients with the ESR1 mutation taking this combination experienced a median of 10 months before their cancer progressed, compared to 5.5 months for those on standard hormone therapy.
Common side effects include mouth and lung inflammation, rash, fatigue, diarrhea, pain, and nausea. The prescribing information includes warnings for slow heart rate and potential harm to a developing fetus. The annual list price is approximately $270,000.